Highlight
- Genomic testing is not currently recommended for universal screening in psychiatry due to modest predictive power and possible psychological harms.
- Rare high-impact genetic variants have value in early clinical settings for diagnosis, prognosis, and personalized management.
- Polygenic scores may aid in risk stratification within high-risk psychiatric populations when combined with non-genetic factors.
- Pharmacogenomics and genomics-informed somatic risk assessment offer important opportunities for secondary and tertiary prevention in mental illness.
